Ahead of FDA decision on BTK drug, Amgen-partnered BeiGene is one step closer to China OK for PD-1
China is reportedly approving its 6th PD-1(L)1 drug in just over a year — and Amgen will be pleased with this one.
The OK for tislelizumab …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
